Research and Development
Our research focuses on addressing ADME-Tox requirements and pioneering preclinical solutions.
R&D PIPELINE
Preclinical Research
ReadyCell manufactures ready-to-use cell-based models as a compelling alternative to animal testing, offering efficient solutions to improve candidate success in preclinical drug development. In this context, we continuously expand our product portfolio to align with new therapeutic agents, the evolving demands of the pharmaceutical industry and research groups, and the valuable inputs from regulatory authorities.
Thanks to it, ReadyCell is at the forefront of the ADME-Tox segment, providing cell-based models able to investigate the mechanisms involved in intestinal drug toxicity, drug-transporter interactions and active and passive drug absorption and secretion.
Years of research
Developments and findings
Collaborative projects
Preclinical research
New applications for existing cell-based models
Besides applying ReadyCell’s products in the ADME-Tox segment, we are exploring new applications for our developments that can provide insights into the underlying mechanism of cellular biology in health and disease. We expect these applications to benefit pharmaceutical, nutraceutical, food, feed, and chemical companies.
Our primary areas of interest include the following:
Permeability for non-small molecules
Our team is actively expanding the range of permeability and transport-drug interaction studies for substances other than small molecules: peptides, nutraceuticals and nanoparticles.
Inflammation
Given its promising and positive results, we are currently revalidating the CacoGoblet model for screening the potential anti-inflammatory activity of compounds based on TEER value changes.
Alcohol-induced gut barrier dysfunction
Our team is ultimately validating the application of the CacoReady model for ethanol-induced toxicity research.
Do you have a passion for advancing drug discovery and biomedical research?
ReadyCell scientists are available to discuss tailored projects indicated for drug development and preclinical studies.
PRECLINICAL RESEARCH
Ongoing developments
We are interested in expanding our pipeline, which we actively pursue through several collaborations and projects:
Organ-on-a-chip (OoC)
ReadyCell is currently developing a microfluidic organ-on-a-chip (OoC) that allow us to offer advanced solutions in the OoC domain. In this sense, we participate in diverse research projects to emulate gut and liver microenvironment and for articular tissue regeneration.
Blood-Brain Barrier (BBB)
We will surpass BBB’s existing models by evaluating the rate and extent of drug delivery across this barrier, opening new opportunities in neurological research.
Cardiomyocytes (iPSC)
Through active collaborations, we are developing a ready-to-use cardiotoxicity assay based on induced pluripotent stem cell (iPSC)-derived cardiomyocytes that will significantly enhance the accuracy and effectiveness of detecting cardiac adverse events in drug screening.
Hepatocytes
Our research aims to develop user-friendly human hepatocytes, essential tools for characterizing the metabolism and hepatotoxicity of xenobiotics. These liver models are vital tools for the pharmaceutical industry, facilitating comprehensive drug metabolism and safety assessment.
Shipping Medium for biological samples
We adapt the formula of our specialized gel-patented medium to deliver worldwide floating cells and biological samples at room temperature.
Public-private partnership projects
Collaborations
ReadyCell is involved in several research projects with public and private organizations to push the boundaries of scientific innovation.
CIEN 2019 – SEGURAM
SEGURAM is a national funding project with the participation of seven companies with operational establishment in Spain. The project is addressed to develop new sustainable strategies along the meat industry’s entire value chain to increase food productivity, quality, and safety while reducing the use of antibiotics.
MCIN/AEI 2022 – 3DLIVER
3DLIVER is a national funding project oriented toward developing next-generation in vitro liver models for preclinical research in drug development. Readycell is the project coordinator of 3DLIVER and contributes to adapting liver models into a ready-to-use format for commercialization.
MISIONES 2020 – BIOPRINTIA
BioprintIA is a consortium of six Spanish companies and two technological centers collaborating across disciplines to conduct industrial research into novel treatments for osteoarticular injuries. Personalized bioimplants use 3D bioprinting techniques and artificial intelligence (IA) to achieve such an ambitious global objective.
MCIN/AEI 2022 – MPS-LOC
The MPS-LOC project converges microfluidics, 3D printing, human-derived liver cells, and liver-derived bio-inks to develop a liver-on-chip device with high predictive value. In this context, ReadyCell pursues the implementation of organ-on-a-chip technology as a common screening tool in drug preclinical studies.
HORIZON 2020 – FETOPEN
StretchBio is a project under the European Union’s Programme Horizon 2020 to develop an innovative two-dimensional force sensor based on an array of nanopillars. This sensor will continuously monitor and quantify mechanical stresses in ex vivo fresh tissue biopsies for drug screening purposes in personalized cancer medicine.
BIBLIOGRAPHY AND ARTICLES
Publications
- Ma, L., Tu, H., & Chen, T. (2023). Postbiotics in Human Health: A Narrative Review. Nutrients, 15(2), 291.
- Esquena-Moret, J. (2022). A Review of Xyloglucan: Self-Aggregation, Hydrogel Formation, Mucoadhesion and Uses in Medical Devices. Macromol, 2(4), 562–590.
- Milani, N., et al. (2022). Application of a gut–liver-on-a-chip device and mechanistic modelling to the quantitative in vitro pharmacokinetic study of mycophenolate mofetil. Lab On A Chip, 22(15), 2853-2868.
- Ortega-Anaya, J., et al. (2021). Milk fat globule membrane phospholipids modify adhesion of Lactobacillus to mucus-producing Caco-2/Goblet cells by altering the cell envelope. Food Research International. 146. 110471.
- Servi, B., Ranzini, F. (2017). Protective efficacy of antidiarrheal agents in a permeability model of Escherichia coli-infected CacoGoblet cells. Future Microbiology, vol. 12, no. 16.
- Fraile, B., et al. (2017). Xyloglucan, hibiscus and propolis for the prevention of urinary tract infections: results of in vitro studies. Future Microbiology, vol. 12, no. 8.
- Kenzaoui, B.H., Vilà, M., Juillerat-Jeanneret, L. (2012). Evaluation of uptake and transport of cationic and anionic ultrasmall iron oxide nanoparticles by human colon cells. Int J Nanomedicine. 2012; 7: 1275–1286. doi: 10.2147/IJN.S26865.
- Miyamoto, R., et al. (2019). The Impact of Endogenous Breast Cancer Resistance Protein on Human P-Glycoprotein-Mediated Transport Assays Using LLC-PK1 Cells Transfected With Human P-Glycoprotein. Journal of Pharmaceutical Sciences, Vol. 108, Issue 3, pp. 1085-1089. https://doi.org/10.1016/j.xphs.2018.10.012.
- Aubets, J., Jansat, J-M., Salva, M., et al. (2019). No evidence for interactions of dimethylfumarate (DMF) and its main metabolite monomethylfumarate (MMF) with human cytochrome P450 (CYP) enzymes and the P-glycoprotein (P-gp) drug transporter. Pharmacol Res Perspect. 2019;e00540. DOI: 10.1002/prp2.540.
- Mukkavilli, R., Jadhav, G., Vangala, S. (2017). Evaluation of Drug Transport in MDCKII-Wild Type, MDCKII-MDR1, MDCKII-BCRP and Caco-2 Cell Lines. Current Pharmaceutical Biotechnology, Vol. 18, No. 14, pp. 1151-1158(8). https://doi.org/10.2174/1389201019666180308091855.
Resources
At ReadyCell, we are dedicated to sharing our knowledge and resources through different formats of interest. Explore our latest releases below.
